Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
TheFly reported on June 24 that Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of SLN with an Overweight rating and no price target.
Silence Therapeutics Plc (SLN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 2,911,438 | $15,343,278 | 0.43% | |
| 2. | Redmile Group Jeremy Green | 2,164,777 | $11,408,375 | 0.76% | |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,146,731 | $11,313,272 | +40% | 0.42% |
| 4. | Citadel Investment Group Ken Griffin | 1,234,807 | $6,507,433 | +406% | 0% |
| 5. | Millennium Management Israel Englander | 1,074,191 | $5,660,987 | +63% | 0% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,063 | $121,472 | 0% |
News See All
10 Most Promising Cancer Stocks According to Wall Street Analysts
Regardless of the state of the economy, the pharmaceutical business has continued to be one of the healthcare market's most robust sectors thanks to the consistent need for medications, vaccinations, ...
10 Small Cap Stocks with Potential to Rise 1000 Percent
Small-cap stocks have returned to the market’s risk conversation in 2026.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
Silence Therapeutics plc (NASDAQ:SLN) Q4 2024 Earnings Call Transcript
Gem Hopkins: Good morning and good afternoon, everyone. Thank you for joining us today. My name is Gem Hopkins, Vice President of Investor Relations and Corporate Communications at Silence.
10 Oversold Global Stocks To Buy Right Now
'There are decades where nothing happens, and there are weeks where decades happen" is apt when starting a piece about global stocks.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics plc misses on earnings expectations. Reported EPS is $-0.47 EPS, expectations were $-0.25.
Silence Therapeutics plc (NASDAQ:SLN) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast. Please be advised that today's conference is being recorded.
8 Medical Stocks to Buy According to Mitchell Blutt's Consonance Capital
In this article, we will be looking at the 8 medical stocks to buy according to Mitchell Blutt's Consonance Capital.
Hedge Fund Resource Center